CompletedPhase 1

The Effect of Topiramate on Etonogestrel Concentrations in Contraceptive Implant Users

United States48 participantsStarted 2018-03-15

Plain-language summary

A prospective, non-inferiority study to evaluate the pharmacokinetic effect of topiramate on serum Etonogestrel (ENG) levels in contraceptive implant users.

Who can participate

Age range18 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Cytochrome P-450 enzyme inducers, inhibitors, or substrates, and
✕. are not willing to abstain from any of these medications or supplements during the entire course of the study.

What they're measuring

Serum Etonogestrel Concentrations

Timeframe: Enrollment (Baseline), 4 weeks (Visit 2), 5 weeks (Visit 3), 6 weeks (Visit 4)

Trial details

NCT IDNCT03335163

SponsorUniversity of Colorado, Denver

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-04-22

Results submitted2022-03-17

View on ClinicalTrials.gov More Migraine trials